Catalent to Showcase CDMO Solutions at INTERPHEX Week Tokyo 2025
ByAinvest
Friday, Jun 20, 2025 8:25 pm ET1min read
DMO--
Mammalian-based expression systems, which account for 72.5% of the global market share in 2025, are expected to remain dominant through 2035. These systems are particularly suited for producing monoclonal antibodies, vaccines, and gene therapies. Microbial-based systems, while cheaper, will grow more slowly and play a smaller role in the market, contributing to USD 7.01 billion by 2035 [1].
Monoclonal antibodies (mAbs) are expected to remain the biggest source of revenue, growing from USD 4.93 billion in 2025 to USD 12.95 billion by 2035, at an annual growth rate of 10.2%. Recombinant proteins and vaccines are also projected to grow steadily, with CAGRs of 7.6% and 8.7%, respectively [1].
Commercial-scale manufacturing is expected to generate the largest share of revenue, growing from USD 6.86 billion in 2025 to USD 17.50 billion by 2035. This growth is driven by the steady expansion of approved biologic drugs and outsourcing to reduce investment costs and regulatory challenges [1].
Catalent, a leading CDMO, will exhibit at Interphex Tokyo 2025, showcasing its end-to-end solutions for oral small molecules, consumer health, and biologics. The company will highlight its expertise in development, clinical supply, and commercial manufacturing, as well as participate in speaking engagements and host a networking reception [2].
References:
[1] https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market
[2] https://www.catalent.com/news-events/events/interphex-tokyo-2025
Catalent will exhibit at Interphex Tokyo 2025, featuring end-to-end CDMO solutions for oral small molecules, consumer health, and biologics. The company will showcase its expertise in development, clinical supply, and commercial manufacturing. Catalent will also participate in speaking engagements and host a networking reception during the event.
The biopharmaceutical contract manufacturing market is projected to grow from USD 11.23 billion in 2025 to USD 26.93 billion by 2035, at a CAGR of 8.8% [1]. This growth is driven by limited in-house capabilities, the rising complexity of biologics, and increasing outsourcing of specialized services.Mammalian-based expression systems, which account for 72.5% of the global market share in 2025, are expected to remain dominant through 2035. These systems are particularly suited for producing monoclonal antibodies, vaccines, and gene therapies. Microbial-based systems, while cheaper, will grow more slowly and play a smaller role in the market, contributing to USD 7.01 billion by 2035 [1].
Monoclonal antibodies (mAbs) are expected to remain the biggest source of revenue, growing from USD 4.93 billion in 2025 to USD 12.95 billion by 2035, at an annual growth rate of 10.2%. Recombinant proteins and vaccines are also projected to grow steadily, with CAGRs of 7.6% and 8.7%, respectively [1].
Commercial-scale manufacturing is expected to generate the largest share of revenue, growing from USD 6.86 billion in 2025 to USD 17.50 billion by 2035. This growth is driven by the steady expansion of approved biologic drugs and outsourcing to reduce investment costs and regulatory challenges [1].
Catalent, a leading CDMO, will exhibit at Interphex Tokyo 2025, showcasing its end-to-end solutions for oral small molecules, consumer health, and biologics. The company will highlight its expertise in development, clinical supply, and commercial manufacturing, as well as participate in speaking engagements and host a networking reception [2].
References:
[1] https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market
[2] https://www.catalent.com/news-events/events/interphex-tokyo-2025
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet